Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Clearstream expands global footprint for vascular products

This article was originally published in Clinica

  • News

Executive Summary

AIM-listed ClearStream Technologies (Co Wexford, Ireland) has widened its international sales network after enlisting five new distributors for its coronary and peripheral vascular products. The firm has appointed Oslo-based VingMed to cover Norway, Sweden and Denmark. These three markets, says ClearStream, account for over 15,000 lower limb procedures each year. In the Middle East, Cairo-based EgyptCare and AGP, in Tehran, will cover Egypt and Iran, respectively. For the Asia-Pacific region, Clearstream has appointed Mulya Husada Jaya to cover Indonesia, and Biodevices to cover the Philippines. All the distributors will be selling devices from ClearStream's coronary and peripheral portfolios, except VingMed, which will only sell the company's peripheral products.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

See All
UsernamePublicRestriction

Register

MT096851

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By